A Lithium and Carbamazepine Combination in the Treatment of Bipolar Disorder–A Preliminary Report

  title={A Lithium and Carbamazepine Combination in the Treatment of Bipolar Disorder–A Preliminary Report},
  author={K Inoue and Shiro Arima and K. Tanaka and Yoshiki Fukui and Nobukatsu Kato},
  journal={Psychiatry and Clinical Neurosciences},
  • K. InoueS. Arima N. Kato
  • Published 1 December 1981
  • Psychology, Medicine
  • Psychiatry and Clinical Neurosciences
Abstract: A lithium and carbamazepine combination was reported in five patients with bipolar disorder (DSM‐III), who had not received benefits from conventional treatments. Patients 1, 2 and 4 showed favorable antimanic responses to carbamazepine used in combination with lithium carbonate. Patient 3 did not respond well to either lithium or carbamazepine alone, but improved dramatically on the simultaneous administration of the two drugs. The prophylactic benefit was observed in two patients… 

Efficacy and Safety of Lithium-Carbamazepine Combination in Mania

Despite the demonstrated efficacy of lithium carbonate during acute episodes of mania and as a prophylactic agent in bipolar disorders, 20–25% of patients fail to respond to this treatment.1,2 Some

Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment‐resistant mania

Six of 7 manic patients who had previously been largely refractory to lithium alone, and who still showed substantial mania after several weeks of double‐blind treatment with carbamazepine, improved following the blind addition of lithium.

Perspectives on the use of anticonvulsants in the treatment of bipolar disorder.

The preliminary data evaluating the efficacy of newer anticonvulsants in bipolar patients is still limited, but some of the available findings are promising, and these new agents may represent appropriate third choices for refractory bipolar individuals.

Historical Review of Carbamazepine for the Treatment of Bipolar Disorder

The current body of literature describing the use of carbamazepine in bipolar disorder during both the acute and maintenance phases of the disorder is reviewed, including trials of both monotherapy and combination therapy, as well as findings from trials that included patients with rapid cycling and mixed episodes.

Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients.

Combining lithium with carbamazepine yielded substantial benefit but more adverse effects, and hospitalizations per year fell by 36.1%, and median time to recurrence nearly doubled during combination therapy.

Clinical issues in the use of carbamazepine in psychiatry: a review

  • M. Elphick
  • Medicine, Psychology
    Psychological Medicine
  • 1989
Evidence is presented here in support of the efficacy of carbamazepine (CBZ) in a variety of different psychiatric conditions, and it may possibly be more appropriately prescribed to control or prevent these symptoms than as a treatment for a particular disease entity.

The treatment of affective disorder with carbamazepine: Prophylactic synergism of lithium and carbamazepine combination

  • Kishimoto Akira
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1992

Prophylactic Efficacy of Carbamazepine in Affective Disorders

Long-term prophylactic effects of CBZP will be reported and carbamazepine is considered at present to be an alternative to lithium (Li) in the treatment of affective disorders.



Carbamazepine in manic-depressive illness: a new treatment.

The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness. Seven

Effect of carbamazepine in polyuria associated with lithium therapy.

  • K. Ghose
  • Medicine, Psychology
    Pharmakopsychiatrie, Neuro-Psychopharmakologie
  • 1978
It appears that lithium exacerbates carbamazepine induced CNS side-effects or vice versa, the mechanism of which is not very clear, and simultaneous administration of these two drugs should preferably be avoided.

The use of lithium in affective disorders. 3. A double-blind study of prophylaxis in bipolar illness.

Patients receiving lithium had fewer manic and depressive episodes per patient-year than placebo patients, but this difference may have been due to a sample bias produced by a large dropout rate among patients who had manic episodes.

Lithium carbonate, haloperidol, and irreversible brain damage.

Four acutely agitated patients with diagnoses of mania were treated with a combined regimen of lithium carbonate and high doses of haloperidol—a form of therapy that had been used previously in


Patients with the seizure types under consideration and who do not respond to DPH alone or to a DPH-phenobarbital combination can be placed on either carbamazepine or primidone while phenobarbitals is discontinued, suggesting that patients who have a past history of emotional and/or intellectual disturbances may profit more from carbamazetine.

A controlled evaluation of lithium prophylaxis in affective disorders

Lithium carbonate was found to be significantly superior to placebo in the prophylaxis of manic-depressive (bipolar) psychosis in a double-blind crossover trial.

Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study.

The clinical results of an intensive longitudinal double-blind study in 30 manic-depressive and depressed patients are presented and the theoretical implications for the therapeutic use of lithium-carbonate in affective disorders are discussed.

Recurrent depressions and the lithium ion.

Five patients with recurrent depressions, three of whom had typical manic-depressive illnesses, were successfully used to treat lithium, establishing a very suggestive relationship between illnesses previously believed on observational grounds alone to be related.

The Effects of Carbamazepine on Patients with Psychomotor Epilepsy: Results of a Double‐Blind Study

Carbamazepine is effective for treatment of psychomotor epilepsy and is safe when blood and platelet counts are checked, and Behavioral effects were not demonstrable on a double‐blind basis.